P21 A Comparative Analysis of Large Language Models (LLM) Utilised in Systematic Literature Review
The objective of this study was to conduct a comparison of three Large Language Models (LLMs) — AI21 Ultra, OpenAI GPT-4, and Google Vertex Artificial Intelligence (AI) Model Bison in their application to primary screening during a systematic literature review (SLR). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H. Rathi, A. Malik, D.C. Behera, G. Kamboj Tags: Using Artificial Intelligence to Enhance Efficiency in Systematic Reviews and Meta-Analyses Source Type: research
P22 Disrupting Health Economics: Automating Network Meta-Analyses With AI and Large Language Models
The advancement of Large Language Models (LLMs), such as GPT-4, provides opportunities for automating data extraction and analysis in systematic reviews and meta-analyses. However, their practical application in Health Economics and Outcomes Research (HEOR) remains unverified. Our study aimed to evaluate GPT-4's accuracy in replicating a Network Meta-Analysis (NMA) result on overall survival of adult patients with advanced non-small cell lung cancer (NSCLC) post platinum-based treatment and pre-immunotherapy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: T. Reason, B. Malcolm, S. Klijn, J. Langham, A. Gimblett, E. Benbow Source Type: research
P23 Evolving Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews (SLRs)
The objective of current review was to analyse the trends and understand gaps of using AI/ML tools in published SLRs. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Kamra, A. Verma, R. Pagidigummula, I.S. Kohli, R. Goyal, S. Kumar, K. Rtveladze Source Type: research
P24 Improving Efficiency of Living Systematic Literature Reviews (SLR) with Artificial Intelligence (AI): Assisted Extraction of Population, Intervention/Comparator, Outcome, and Study Design (P-I/C-O-S)
SLRs are crucial but time-consuming parts of any evidence-based research. SLR protocols ’ modifications add further complexity. We developed an AI-assisted tool, LiveSTARTTM, which extracts P-I/C-O-S information from citations during SLR review. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Liu, R. Jafar, L.A. Girard, K. Thorlund, M. Rizzo, A. Forsythe Source Type: research
P25 Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search
Lenalidomide, a molecular-targeted agent that binds to cereblon, is active in multiple myeloma (MM), the second most common haematological malignancy. Continuous exposure is associated with efficacy; however, the impact of adherence to lenalidomide oral maintenance therapy on quality of life is unclear. We assessed the available literature to assess the relationship between adherence and patient-reported outcomes (PROs) in lenalidomide-treated MM patients. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K. Ramasamy, M. von Lilienfeld-Toal, C. Maisel, B. Gustavsson, K. B äck, A. Glasmacher, X. Leleu Tags: Adherence to Treatment, Patients' Preferences, and Drug Use across Multiple Diseases Source Type: research
P26 Drug Utilization, Adherence, and Persistence in Parkinson's Disease Patients in a Real-World Setting in Quebec, Canada
The objective of this project was to analyze drug utilization, adherenc e and persistence in a real-world setting, of patients with a diagnosis of PD in Quebec, Canada. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. Baribeau, S. Mohammed, A. Awan, D. Parison, J. Lachaine Source Type: research
P27 How Untruthfulness in Self-Reported Medication Adherence Influences Treatment Preferences: A Discrete Choice Experiment
This study investigated how to induce truthful self-reported adherence and how this can explain heterogeneity in treatment preferences. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Oedingen, R. van Gestel, S. Huls, E. de Bekker-Grob, J. Veldwijk Source Type: research
P28 Medication Non-Adherence in Patients with Varying Levels of Depression Symptoms Measured Using the Medication Adherence Reasons Scale
Depression affects approximately 280 million people worldwide. Literature reports that the overall non-adherence to antidepressants immediately after the start of treatment was 13 to 55.7% and by six months was 52%. However, what is missing in the literature is the extent of non-adherence among individuals based on their level of depression. PHQ-9 score has been used to determine the level of depression as none to minimal, mild, moderate, moderately severe, and severe. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: E. Unni, N. Sternbach, H. Costantino, S. Gupta Source Type: research
P29 Conditional Marketing Authorization – Becoming Increasingly More Common But Increasingly Less Relevant
The European Medicines Agency (EMA) can grant a Conditional Medicines Authorization (CMA) for medicines that treat severe diseases based on less comprehensive clinical data than usual, pending the collection of more comprehensive data post-authorization. This research evaluates how the number of CMAs have evolved over time and their conversion to successful reimbursement. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Macaulay, M. Bear Tags: Impact of Regulatory Affairs on Access Source Type: research
P30 Do Novel Oncology Combination Therapies Have a Place Within the EU Legislative Framework? The Impact of Challenges for Novel Combination Therapies on Equality of Access Between European Patients
Combination therapies have contributed to recent improvements in cancer care but encounter significant challenges impacting patient access. These challenges, and the potential to address them, vary considerably across European countries. Consequently, there is substantial inequality in treatment opportunities which we have documented through quantitative, evidence-based analysis. Additionally, the upcoming European legislative reforms (EU HTA Regulation, EU pharmaceutical legislation) have been considered; these could provide an opportunity to address challenges or further exacerbate existing access problems. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Pistollato, T. Veale, S.J. Ong Source Type: research
P31 Evidence Supporting Regulatory Withdrawals and Quantifying Their Impact on Public Health
To assess trends in the use of evidence to support regulatory actions in Europe, and to identify a model which quantifies public health impact of a subset of these regulatory actions in terms of morbidity. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Lane, E. Lynn, J. Slattery, S. Shakir Source Type: research
P32 Implementation of Early Access Reform in France and Access to Innovation: Impact in Terms of Number of Drugs, Patients Treated, and Cost
The objective of this study was to describe the impact of the reform on the number of drugs in EA, number of patients treated and cost. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: T. Martin, C. Rioufol, N. Martelli, I. Madelaine, I. Borget Source Type: research
P33 Extending the PICOTS Framework for Evidence Syntheses of Digital Health Interventions: Results of a Delphi Consensus Study
Previous research has shown that definitions of digital health-related terms are diverse and ambiguous. Therefore, we aimed to develop a minimum information framework for defining research questions for patient-facing digital health interventions that is sufficiently specific for evidence syntheses in health economics and outcomes research (HEOR). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Z. Zrubka, A. Champion, A.P. Holtorf, R. Di Bidino, J.R. Earla, A. Boltyenkov, M. Tabata-Kelly, C. Asche, A. Burrell Tags: Advancements in Digital Health Interventions: Evidence Syntheses, Value Assessment, and Global Perspectives Source Type: research
P34 Health Technology Assessments of Digital Public Health Interventions in the Southeast Asia - A Systematic Scoping Review
To map and analyze the Health Technology Assessments (HTA) of digital public health interventions in the WHO South East Asian region. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: N. Gudi, E.A.R. S., B. Jahn, U. Siebert, A. Brand Source Type: research
P35 How Perspective Affects the Cost-Effectiveness of Remote Patient Monitoring for Patients With Heart Failure in Different European Countries
This study aims to assess the impact of adding the costs o f informal care and costs of future (non)-medical consumption to the costs of healthcare and long-term care on the cost-effectiveness of remote patient management (RPM) for heart failure. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: H. Mokri, M. Rutten-van M ölken, P. van Baal Source Type: research
